Overview

Early Intervention in COVID-19: Favipiravir Verses Standard Care

Status:
Active, not recruiting
Trial end date:
2021-06-25
Target enrollment:
Participant gender:
Summary
Currently we do not know how best to treat patients infected with COVID-19. This study is looking at whether randomising participants to either favipiravir or to usual care, can help patients with suspected or proven COVID-19 infection.
Phase:
Phase 3
Details
Lead Sponsor:
Chelsea and Westminster NHS Foundation Trust
Collaborators:
FUJIFILM Toyama Chemical Co., Ltd.
Imperial College London
NEAT ID Foundation
Universitaire Ziekenhuizen Leuven
Treatments:
Azithromycin
Favipiravir
Hydroxychloroquine
Zinc
Zinc Sulfate